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HD-IL2 was given to patients with mRCC in a prospec-
tive trial (ClinicalTrials.gov ID: NCT00554515) that
demonstrated an overall response rate of 25%. To iden-
tify predictors of response, we genotyped patients for
single nucleotide polymorphisms (SNPs) in FcgR genes:
FcgR2a, FcgR3a, and FcgR2c. These FcgRs are variably
expressed on immune cells, and bind to the IgG portion
of antibodies, triggering activation.
FcgR2a [SNP = histidine/arginine (H/R); expressed on
neutrophils, monocytes-macrophages and antigen-pre-
senting cells (APCs)] and FcgR3a [SNP = valine/pheny-
lalanine (V/F); expressed on NK cells and some APCs]
impact patient response to immunotherapy [mainly
monoclonal antibody-based (mAb) therapies] in several
malignancies, as both FcgR2a-H and FcgR3a-V have
higher antibody binding affinity than FcgR2a-R or
FcgR3a-F, respectively. FcgR2c, also expressed on NK
cells, has a SNP that regulates its expression [C nucleo-
tide = expression; T nucleotide = non-expression (C/T)].
About 20-40% of individuals express FcgR2c; little is
known about the role of FcgR2c expression in cytokine-
based immunotherapy.
We found associations of FcgR genotypes with patient
response to HD-IL2. Dual combination analyses of
FcgR3a with FcgR2a genotypes revealed significantly
improved %Tumor Shrinkage in patients with either
FcgR3a-VV and/or FcgR2a-HH (n=34) as compared to
those patients genotyped as FcgR3a-VF or FF with
FcgR2a-HR or RR (n=70) (p=0.047). For analyses includ-
ing both FcgR3a and FcgR2c genotypes, significantly
improved OS was seen in those with ≥2 alleles of either
FcgR3a-V and/or FcgR2c-C (n=27) vs. those with < 2
alleles of either FcgR3a-V and/or FcgR2c-C (n=79)
(p=0.013). We further considered combinations that
included the genotypes of all 3 genes; we identified
42 patients with “favorable” genotypes and 64 with
“unfavorable”. We saw significant improvement in the %
Tumor shrinkage (p = 0.033) and a trend for improve-
ment in OS (p = 0.071) in the “favorable genotype”
group.
As reported previously by others, some cancer patients
make endogenous anti-tumor Ab. The association of these
“favorable” FcgR genotypes with outcome suggests there
may be a beneficial interaction of “favorable” FcR geno-
types with endogenous anti-tumor Ab. Favorable FcgRs
may support the induction of in vivo antibody-dependent
cell-mediated cytotoxicity (ADCC) or antibody-dependent
cellular phagocytosis (ADCP). In addition, ADCP by APC
with a favorable pattern of FcgRs, may be playing a role in
enhancing induction of effective adaptive immunity, via
augmented antigen presentation. Further analyses are
needed to validate these exploratory findings and clarify
the mechanisms by which these favorable FcgR genotypes
are associated with improved outcome in these patients
with mRCC treated with HD-IL2.
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